期刊文献+

银杏叶提取物对糖尿病大鼠血清学指标的影响

Effect of Ginkgo biloba Extract on Serological Indexes of Diabetic Rats
原文传递
导出
摘要 目的研究银杏叶提取物(GbE)对糖尿病大鼠血清学指标的影响,探讨其在糖尿病大鼠脂代谢过程中的作用。方法通过腹腔注射链脲佐菌素(STZ)(50mg/kg)建立糖尿病大鼠模型。将模型大鼠随机分为模型对照组(DM)和GbE组,GbE组每日给予GbE提取物,0.83ml/只,DM组每日给予等剂量的生理盐水,均为腹腔注射,另设1组正常大鼠对照。于注射银杏叶提取物的第1和15天采血,检测各组大鼠血清甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)水平,第15天检测大鼠血清中胰岛素和C-肽水平。结果DM组大鼠血清中TG和LDL-C水平随着时间的延长逐渐升高;注射后第15天,GbE组大鼠血清中TG和LDL-C水平均显著低于DM组,HDL-C和C-肽水平显著高于DM组,胰岛素水平与DM组比较,差异无统计学意义。结论银杏叶提取物对糖尿病大鼠的脂代谢具有调节作用,对高糖导致的损伤具有保护作用。 Objective To study the effect of Ginkgo biloba extract (GbE) on serological indexes as well as its role in lipid nletabolism of diabetic rats. Methods Rat model of diabetes was established by injecting i.p. with streptozotocin (STZ). The diabetic rats were divided into GbE and model control (DM) groups and daily injected, i. p. with 0. 83 ml of GbE and physiological saline respectively for 14 d. Healthy rats were served as normal control. The serum samples of rats in various groups were collected on days 1 and 15 after the first injection for determination of triglyceride (TG), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C). The insulin and C-peptide levels in sera of rats were determined on day 15 after the first injection. Results The TG level in sera of rats in DM group increased gradually as the time goes on. On day 15 after the first injection, the TG and LDL-C levels in sera of rats in GbE group were significantly lower, while HDL-C and C-peptide levels were significantly higher than those in DM group. However, no significant difference was observed in the insulin levels of the two groups. Conclusion GbE showed regulatory effect on lipid metabolism of diabetic rats and protective effect on injury caused by high blood suger.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第2期171-173,共3页 Chinese Journal of Biologicals
基金 长春市科学技术局(2007GH2033)
关键词 银杏叶 提取物 糖尿病 脂代谢 Ginkgo b iloba Extract Diabetes Lipid metabolism
  • 相关文献

参考文献11

  • 1Fonseca VA. The metabolic syndrome, hyperlipiddemia, and insulin resistance. Clin Cornerstone, 2005, 7(3): 61-72.
  • 2姚君厘.糖尿病和大血管病变[J].上海医药,2006,27(6):253-256. 被引量:14
  • 3Libby P. Vascular biology of atheroselerosis: overview and state of the art. Am J Cardiol, 2003, 91(3 Suppl 1): 3A-6A.
  • 4Grundy SM, Brewer HB, Cleeman JL, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute / American Heart Association conference on scientific issues related to definition. Circulation, 2004, 109(3): 433-438.
  • 5Welch V, Tang SS. Treatment and control of BP and lipids in patients with hypertension and additional risk factors. Am J Cardiovasc Drugs, 2007, 7(5): 381-389.
  • 6Liang K, Sheu WH, Lee W, et al. Coronary artery disease progression is associated with C-reactive protein and conventional risk factors but not soluble CD 40 ligand. Canadian J Cardiol, 2006, 22 (8): 691-696.
  • 7Haffner SM. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care, 2004, 27 (Suppl 1 ): S568-S$571.
  • 8Wang BS, Yu HM, Chang LW, et al. Protective effects of pu-erh tea on LDL oxidation and nitric oxide generation in macrophage cells. LWT Food Sci Technol, 2008, 41(6): 1122-1132.
  • 9Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J, 2001, 15( 12): 2073-2084.
  • 10Brites F, Zago V, Verona J, et al. HDL capacity to inhibit LDL oxidation in well-trained triathletes. Life Sci, 2006, 78 (26): 3074-3081.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部